Vaxcyte

Update in progress

PCVX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Vaxcyte, Inc. is a clinical-stage vaccine company focused on conjugate and protein vaccines to prevent bacterial infections. Its lead program is VAX-24, a 24-valent carrier-sparing pneumococcal vaccine for invasive disease in infants, followed by VAX-31 (31-valent) for IPD in all ages, VAX-A1 for Group A Streptococcus, VAX-PG for periodontitis, VAX-GI for dysentery/Shigella, and VAX-XL, a third-generation PCV. Formerly SutroVax, renamed in 2020, based in San Carlos, CA, since 2013.

Company score

Sentiment: 0.44; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.02; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.25; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.27; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive